The Technical Analyst
SCYNEXIS Inc [SCYX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
SCYNEXIS Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.49% $1.440
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 54.37 mill |
| EPS: | 1.390 |
| P/E: | 1.040 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 37.75 mill |
| Avg Daily Volume: | 0.200 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 1.040 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.02x |
| Company: PE 1.040 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.346 - 1.534 ( +/- 6.53%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-16 | Sukenick Scott | Sell | 15 179 | Common Stock |
| 2024-01-26 | Angulo Gonzalez David | Buy | 290 590 | Common Stock |
| 2024-01-26 | Angulo Gonzalez David | Buy | 431 030 | Employee Stock Option (Right to Buy) |
| 2024-01-26 | Macleod Ivor | Buy | 215 515 | Employee Stock Option (Right to Buy) |
| 2024-01-26 | Macleod Ivor | Buy | 143 675 | Common Stock |
| INSIDER POWER |
|---|
| 98.26 |
| Last 93 transactions |
| Buy: 4 299 100 | Sell: 614 179 |
Forecast:
16:00 - $1.460
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.460
Forecast 2: 16:00 - $1.460
Forecast 3: 16:00 - $1.460
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.440 (2.49% ) |
| Volume | 0.131 mill |
| Avg. Vol. | 0.200 mill |
| % of Avg. Vol | 65.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SCYX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SCYX
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-04-09 16:05:00 - Press Release
Scynexis To Present Preclinical Data On Second Generation Fungerp Scy-247 At The 34th European Congress Of Clinical Microbiology And Infectious Diseases (eccmid)
Jersey city, n.j., april 09, 2024 (globe newswire) -- scynexis, inc. (nasdaq: scyx), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate scy-247 at the 34th european congress of clinical microbiology and infectious diseases (eccmid) in barcelona, spain from april 27-30, 2024.
2024-03-28 16:01:00 - Press Release
Scynexis Reports Full Year 2023 Financial Results and Provides Corporate Update
Jersey city, n.j., march 28, 2024 (globe newswire) -- scynexis, inc. (nasdaq: scyx), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended december 31, 2023.
2024-01-29 17:15:00 - Press Release
Scynexis Presented Preclinical Data On Second Generation Fungerp Scy-247 Against Mucormycosis At The 11th Advances Against Aspergillosis And Mucormycosis Conference
Jersey city, n.j., jan. 29, 2024 (globe newswire) -- scynexis, inc. (nasdaq: scyx), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate scy-247.
2024-01-08 04:00:00 - Press Release
Final Deadline Today: The Schall Law Firm Encourages Investors In Scynexis, Inc. With Losses To Contact The Firm
Los angeles, ca / accesswire / january 8, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against scynexis, inc. ("scynexis" or "the company") (nasdaq:scyx) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between march 31, 2023 and september 22, 2023, inclusive (the "class period"), are encouraged to contact the firm before january 8, 2024.
2024-01-08 01:00:00 - Press Release
Final Scyx Investor Deadline: Bronstein, Gewirtz & Grossman Llc Announces That Scynexis, Inc. Investors With Substantial Losses Have Opportunity To Lead Class Action Lawsuit!
New york , jan. 8, 2024 /prnewswire/ -- bronstein, gewirtz & grossman, llc a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against scynexis, inc. ("scynexis" or "the company") (nasdaq: scyx) and certain of its officers. class definition: this lawsuit seeks to recover damages against defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired scynexis securities between march 31, 2023 and september 22, 2023, inclusive (the "class period").
Latest News
2024-04-09 16:05:00 - GlobeNewsWire
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024.
2024-01-05 08:30:00 - GlobeNewsWire
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.
2023-12-18 18:46:23 - Seeking Alpha
Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'
Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sales of over $500M. Ibrexafungerp commercialization and clinical development was paused due to manufacturing concerns, resulting in a 50% dip in SCYX valuation. However, the issue is expected to be resolved within few months. Considering cash runway >2 years, SCYX is sufficiently funded to resolve the issue and start having an income from milestones/royalties.
2023-09-26 19:54:24 - Seeking Alpha
Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)
We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturing recalls can take months to resolve, and for a single-product biotech, we see further downside to the stock price. Concerns around the impact on clinical trials, partnership with GSK, and uncertainty surrounding hospital-based fungal infection trials remain a key focus/risk moving forward.
2023-09-04 15:02:04 - Zacks Investment Research
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
2023-08-28 22:17:02 - InvestorPlace
Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now
As a rule of thumb, you should stay away from penny stocks. When you see shares priced near a buck (or even below), there's usually a reason for it – and not a good one.
2023-08-28 08:00:00 - GlobeNewsWire
SCYNEXIS to Participate in September Investor Conferences
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences.
2023-05-19 16:57:45 - Seeking Alpha
Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating
SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. Phase 3 MARIO trial data, pivotal for potential label expansion, is anticipated in 1H'24. The study focuses on invasive candidiasis patients.
2023-05-19 09:22:00 - Newsfile Corp
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C.
2023-05-11 09:56:18 - Zacks Investment Research
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.51 per share a year ago.